Depression and other psychological health problems among methamphetamine dependent patients in treatment: Implications for assessment and treatment outcome

Australian Psychologist

Volumn 40, Issue 2, 2005, Pages 96-108

  Dyer, K R ^a   Cruickshank, G C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23744495312     PISSN: 00050067     EISSN: None     Source Type: Journal    
DOI: 10.1080/00050060500094647     Document Type: Article

References (61)

1. Aharonovich, E., Nunes, E., & Hasin, D. (2003) Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioural treatment. Drug and Alcohol Dependence, 71, 207-211.
2. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders (4th ed., text revision). Washington DC: The Author.
3. Anggard, E., Jonsson, L. E., Hogmark, A. L., & Gunne, L. M. (1973). Amphetamine metabolism in amphetamine psychosis. Clinical Pharmacology and Therapeutics, 14, 870-880.
4. Arean, P., McQuaid, J., Munoz, R. (1997) Mood disorders: Depressive disorders. In S. Turner, & M. Hersen(Eds-), Adult psychopathology and diagnosis (3rd ed., pp. 230-255). New York: John Wiley & Sons.
5. Australian Bureau of Statistics (2001). 2001 Census Basic Community Profile and Snapshot. Retrieved 21 November 2003, from Australian Bureau of Statistics http://www.abs.gov.au/ausstats
6. Beck, A., Steer, R., & Brown, G. (1996) BDI-II manual. San Antonio: The Psychological Corporation.
7. Bell, D. S. (1973). The experimental reproduction of amphetamine psychosis. Archives of General Psychiatry, 29, 35-40.
8. Buckley, T., Parker, J., Heggie, J. (2001) A psychometric evaluation of the BDI-II in treatment seeking substance abusers. Journal of Substance Abuse Treatment, 20, 197- 204.
9. Carey, K., & Correia, C. (1998) Severe mental illness and addictions: assessment considerations. Addictive Behaviors, 23, 735-748.
10. Comer, S. D., Hart, C. L., Ward, A. S., Haney, M., Foltin, R. W., & Fischman, M. W. (2001). Effects of repeated oral methamphetamine administration in humans. Psychopharmacology, 155 (4):397-404.
11. Cone E. J. (1993) Saliva testing for drugs of abuse. Annals of the New York Academy of Science, 694, 91-127
12. Cruickshank, C. C. & Dyer, K. R. (2003) In-patient symptom-triggered management of amphetamine withdrawal: clinical practice and treatment outcome. Perth: Next Step Specialist Drug and Alcohol Services.
13. Davidson, C., Gow, A. J., Lee, T. H., & Ellinwood, E. H. (2001). Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Research: Brain Research Review, 36, 1-22.
14. Dawe, S., & Mattick, R. (1997) Review of diagnostic screening instruments for alcohol and other drug use and other psychiatric disorders. Canberra: Australian Government Publishing Service.
15. Derlet, R. W., Rice, P., Horowitz, B. Z., & Lord, R. V. (1989). Amphetamine toxicity: experience with 127 cases. Journal of Emergency Medicine, 7, 157-161.
16. Dozois, D., Dobson, K., Ahnberg, J. (1998) A psychometric evaluation of the BDI-II. Psychological Assessment, 10, 83-89.
17. Drug and Alcohol Office (2003). 2001 National drug strategy household survey: First results for Western Australia: Data tables. Retrieved 6 May 2004, from Drug and Alcohol Office http://www.dao.health.wa.gov.au/index.cfm?section = pubs
18. Drug and Alcohol Office (2004). Alcohol and Drug Information Service Parent Drug Information Service. Bulletin 6. Drug and Alcohol Office. Retrieved 6 May 2004, from Drug and Alcohol Office http://www.dao.health.wa.gov.au/index. cfm?section = pubs
19. Dyer, K. R., Marsh, A., & LaVincente, S. (2003) A psychometric evaluation of the Beck Depression Inventory-II among drug dependent patients. Paper presented at the combined Australian Professional Society on Alcohol and Other Drugs (APSAD) and National Methadone Conference, Brisbane, November 16-19, 2003
20. Dyer, K. R., Taylor, H., Ilett, K., & Wilkinson, C. (2003) Saliva, a novel matrix for identifying methamphetamine and cannabis use among dependent patients. Paper presented at the combined Australian Professional Society on Alcohol & Other Drugs (APSAD) and National Methadone Conference, Brisbane, November 16-19, 2003.
21. Ellinwood, E. H. (1967). Amphetamine psychosis: I. Description of the individuals and the process. Journal of Nervous and Mental Disease, 144, 273-283.
22. Fetherston, J., & Lenton, S. (2004). WA drug trends 2003: Findings from the Illicit Drug Reporting System (IDRS) (NDARC Technical Report No. 179). Perth WA, Australia: National Drug Research Institute, Curtin University.
23. Fleckenstein, A. E., Gibb, J. W., & Hanson, G. R. (2000). Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. European Journal of Pharmacolology, 406, 1-13.
24. Gossop, M. R., Bradley, B. P., & Brewis, R. K. (1982). Amphetamine withdrawal and sleep disturbance. Drug and Alcohol Dependence, 10, 177-183.
25. Griffith, J. D., Cavanaugh, J. H., Held, J., & Oates, J. A. (1970). Experimental psychosis induced by the administration of damphetamine. In E. Costa, & S. Garattini, (Eds.), Amphetamines and related compounds; Proceedings of the Mario Negri Institute for Pharmacological Research, Milan, Italy (pp 897 -904). New York: Raven Press.
26. Haeckel, R., & Hanecke, P. (1996). Application of saliva for drug monitoring. An in vivo model for transmembrane transport. European Journal of Clinical Chemistry and Clinical Biochemistry, 34, 171-91.
27. Hando, J., Topp, L., & Hall, W. (1997). Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug and Alcohol Dependence, 46, 105-113.
28. Hargreaves, K., & Lenton, S. (2002). Findings from illicit drug reporting system (IDRS) (NDARC Technical Report No. 134). Perth WA, Australia: National Drug Research Institute, Curtin University.
29. Hart, C. L., Ward, A. S., Haney, M., Foltin, R. W., & Fischman, M. W. (2001). Methamphetamine self-administration by humans. Psychopharmacology, 157, 75-81.
30. Hawke, J. M., Jainchill, N., & De Leon, G. (2000). Adolescent amphetamine users in treatment: Client profiles and treatment outcomes. Journal of Psychoactive Drugs, 32, 95-105.
31. Hawks, D., Mitcheson, M., Ogborne, A., & Edwards, G. (1969). Abuse of methylamphetamine. British Medical Journal, 1 (659), 715-721.
32. Iwanami, A., Sugiyama, A., Kuroki, N., Toda, S., Kato, N., Nakatani, Y., et al. (1994). Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan. A preliminary report. Acta Psychiatrica Scandinavia, 89, 428-432.
33. Jenkins, A., Oyler, J., & Cone, E. (1995) Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. Journal of Analytic Toxicology, 25, 670 - 679.
34. Kalechstein, A. D., Newton, T. F., Longshore, D., Anglin, M .D., van Gorp, W. G., & Gawin, F. H. (2000). Psychiatric comorbidity of methamphetamine dependence in a forensic sample. Journal of Neuropsychiatry and Clinical Neuroscience, 12, 480-484.
35. Martin, W. R., Sloan, J. W., Sapira, J. D., & Jasinski, D. R. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12, 245-258.
36. McGregor, C., Srisurapanont, M., Jittiwutikan, J., Laobhripatr, S., Wonttan, T., & White, J. M. (2003). Mapping the nature, time-course and severity of methamphetamine withdrawal. Poster presented at College on Problems of Drug Dependence, 2003 Annual Meeting. Retrieved 20 November 2003, from http://biopsych.com:81/cpdd03_web/FMPro
37. Milby, J., Schumacher, J., & Stainback, R. (1997). Psychoactive substance use disorders: Drugs. In S. Turner, & M. Hersen (Eds.), Adult psychopathology and diagnosis (3rd ed., pp. 159-202). New York: John Wiley & Sons.
38. Murray, J. B. (1998). Psychophysiological aspects of amphetamine- methamphetamine abuse. Journal of Psychology 132, 227-237.
39. Newcombe, K., & Dyer, K. (2003) 2005 Next Step Consumer Survey. Perth: Next Step Specialist Drug and Alcohol Services.
40. Newton, T., Cook, I., Kalechstein, A., Duran, S., Monroy, F., Ling, W., et al. (2003). Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clinical Neurophysiology, 114, 410-415.
41. Nordahl, T. E., Salo, R., & Leamon, M. (2003). Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. Journal of Neuropsychiatry and Clinical Neuroscience, 15: 317-325.
42. Nunes, E., Donovan, S., Brady, R., & Quitkin, F. (1994). Evaluation and treatment of mood and anxiety disorders in opioid dependent patients. Journal of Psychoactive Drugs, 26, 147-153.
43. Ornstein, T., Iddon, J., Baldacchino, A., Sahakian, B., London, M., Everitt, B., et al. (2000) Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology, 23, 113-126.
44. Osman, A., Downs, W., Barrios, W., Kopper, B., Guttierez, P., & Chiros, C. (1997) Factor structure and psychometric characteristics of the BDI-II. Journal of Psychopathology and Behavioral Assessment, 19, 359-376.
45. Oswald, I., & Thompson, M. (1963). Amphetamine and phenmetrazine addiction. British Medical Journal 5354, 427-431.
46. Rouen, D., Dolan, K., & Kimber, J. (2001) A review of drug detection testing and an examination of urine, hair, saliva and sweat (Technical Report No. 120). Sydney: National Drug & Alcohol Research Centre, University of NSW.
47. Salo, R., Nordahl, T. E., Possin, K., Leamon, M., Gibson, D. R., Galloway, G. P., et al. (2002). Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Research, 111, 65-74.
48. Scott, J., Gilvarry, E., & Farrell, M. (1998). Managing anxiety and depression in alcohol and drug dependence. Addictive Behaviors, 23, 919-931.
49. Seiden, L. S., Sabol, K. E., & Ricaurte, G. A. (1993). Amphetamine: effects on catecholamine systems and behavior. Annual Review of Pharmacology and Toxicology, 33, 639-677.
50. Sekine, Y., Iyo, M. , Ouchi, Y., Matsunaga, T., Tsukada, H., Okada, H., et al. (2001). Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. American Journal of Psychiatry, 158, 1206-1214.
51. Srisurapanont, M., Jarusuraisin, N., & Jittiwutikan, J. (1999). Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Australian and New Zealand Journal of Psychiatry, 33, 89-93.
52. Srisurapanont, M., Jarusuraisin, N., & Kittirattanapaiboon, P. (2001). Treatment for amphetamine withdrawal. Cochrane Database of Systematic Reviews, 4, Retrieved 20 April 2002, from http://www.cochrane.org/
53. Topp, L., Degenhardt, L., Kaye, S., & Darke, S. (2002). The emergence of potent forms of methamphetamine in Sydney, Australia: A case study of the IDRS as a strategic early warning system. Drug and Alcohol Review, 21, 341-348.
54. Vincent, N., Shoobridge, J., Ask, A., Allsop, S., & Ali, R. (1998). Physical and mental health problems in amphetamine users from metropolitan Adelaide, Australia. Drug and Alcohol Review, 17, 187-195.
55. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., et al. (2001). Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. Journal of Neuroscience, 21, 9414-9418.
56. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., et al. (2001). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry, 158, 377-382.
57. Watson, R., Hartmann, E., & Schildkraut, J. J. (1972). Amphetamine withdrawal: Affective state, sleep patterns, and MHPG excretion. American Journal of Psychiatry, 129, 263-269.
58. White, R. (2000). Dexamphetamine substitution in the treatment of amphetamine abuse: An initial investigation. Addiction, 95, 229-238.
59. Wyatt, S. A., & Zidonis, D. (1998). Psychological and psychiatric consequences of amphetamines. In R. E. Tarter, R. T. Ammerman, & P. J. Ott (Eds.), Handbook of substance abuse: Neurobehavioural pharmacology (pp. 529-544). New York: Plenum Press.
60. Yui, K., Goto, K., Ikemoto, S., & Ishiguro, T. (2000). Stress induced spontaneous recurrence of methamphetamine psychosis: The relation between stressful experiences and sensitivity to stress. Drug and Alcohol Dependence, 58, 67-75.
61. Zweben, J. E., Cohen, J. B., Christian, D., Galloway, G. P., Salinardi, M., Parent, D., et al. (2004) Psychiatric symptoms in methamphetamine users. American Journal on Addictions, 13, 181-190.